Compare · CALT vs TVTX
CALT vs TVTX
Side-by-side comparison of Calliditas Therapeutics AB (CALT) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CALT and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- TVTX is the larger of the two at $4.38B, about 8.0x CALT ($550.4M).
- TVTX has hit the wire 15 times in the past 4 weeks while CALT has been quiet.
- TVTX has more recent analyst coverage (25 ratings vs 3 for CALT).
- Company
- Calliditas Therapeutics AB
- Travere Therapeutics Inc.
- Price
- $41.09+4.82%
- $47.08+2.83%
- Market cap
- $550.4M
- $4.38B
- 1M return
- -
- +10.28%
- 1Y return
- -
- +216.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 15
- Recent ratings
- 3
- 25
Calliditas Therapeutics AB
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest CALT
- SEC Form 15F-12B filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB
- SEC Form 25-NSE filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB
- SEC Form EFFECT filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB
- Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
- SEC Form 25 filed by Calliditas Therapeutics AB
- SEC Form S-8 POS filed by Calliditas Therapeutics AB
Latest TVTX
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
- SEC Form 8-K filed by Travere Therapeutics Inc.
- Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
- Director Williams Brinkley Ruth was granted 4,000 shares, increasing direct ownership by 16% to 29,750 units (SEC Form 4)
- Director Meckler Jeffrey A was granted 4,000 shares, increasing direct ownership by 5% to 91,500 units (SEC Form 4)
- Director Orwin John A was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Poole Sandra was granted 4,000 shares, increasing direct ownership by 13% to 34,000 units (SEC Form 4)
- Director Squarer Ron was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Baynes Roy D. was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)